MG217 Cream Recall Lawsuit | Do You Have a Case? (2026)

Pharmacal has issued a nationwide, voluntary recall of MG217 Multi-Symptom Treatment Cream & Skin Protectant Eczema Cream. Lab testing on the 6 oz topical tube found it positive for Staphylococcus aureus contamination. The affected lot is 1024088, expiring November 2026. The FDA classified the action Class I, its most serious category. Pharmacal initiated the recall April 24, 2026, and posted the public notice May 8, 2026. The recall’s status remains Ongoing. About 690 tubes reached stores and online orders in the United States and the Bahamas. If yours matches lot 1024088, stop using it, discard it, and watch for signs of infection.

Latest MG217 Cream Recall Updates

May 8, 2026: FDA Posts the Nationwide Recall Notice

Pharmacal, working with the U.S. Food and Drug Administration, posted a nationwide recall notice for one lot of MG217 Cream (lot 1024088) after testing confirmed Staphylococcus aureus contamination [1]. The FDA’s enforcement report lists the recall as D-0553-2026, Class I, initiated April 24, 2026, and classified May 29, 2026. It covers 690 tubes, and its status reads Ongoing, with no termination found [2].

Which MG217 Cream Are Affected?

The recall covers one lot of a single MG217 product sold nationwide through retail and online channels. Check your tube against these details before you use it again:

• Product: MG217 Multi-Symptom Treatment Cream & Skin Protectant Eczema Cream, with 2% colloidal oatmeal
• Size: 6 oz (170 g) tube
• Product code: 5106
• UPC: 012277051067
• Lot number: 1024088
• Expiration date: November 2026

The lot number is stamped in the crimped end of the tube, so check there first rather than relying on the outer box. If your tube carries lot 1024088, it falls inside the recall, whether bought in a store, from a wholesale account, or online through Amazon.

Why Was MG217 Cream Recalled?

MG217 Cream was recalled because testing confirmed the product was contaminated with Staphylococcus aureus. Staph is a bacterium that can cause infection if it enters the body through a cut or wound, according to MedlinePlus [3]. Pharmacal makes MG217 Multi-Symptom Treatment Cream & Skin Protectant Eczema Cream as a topical treatment for skin conditions such as eczema. A contaminated batch reached consumers directly. The batch reached consumers before Pharmacal identified the contamination, so the cream itself carried the hazard rather than a labeling or packaging defect. Some staph infections resist common antibiotics, though other antibiotics can still treat them, per the same MedlinePlus source. This recall is limited to the one affected lot.

Reported Incidents, Injuries, or Illnesses

Pharmacal had not received any reports of adverse events tied to this recall as of the May 8, 2026 recall notice. That absence of reports does not prove no one used the affected lot without harm. A Staphylococcus aureus infection from this lot can take time to appear or to be traced back to the cream. The FDA’s own risk statement warns that using the contaminated cream could cause infections. These range from localized skin problems to severe or life-threatening illness, particularly in people with a weakened immune system or compromised skin. A recall notice and a risk statement describe what could happen. Neither one is a confirmed count of injuries already caused by this product.

What Should Consumers Do?

Anyone with a tube of the recalled MG217 Cream should take these steps:

1. Check your tube’s lot number, printed in the crimped end of the tube, against lot 1024088.
2. Stop using the product immediately if the lot number on your tube matches this recall.
3. Discard the tube rather than returning it to a store shelf or giving it away.
4. Contact Pharmacal at 800-558-6614 or aimho@pharmacalway.com, Monday through Friday from 8am to 5pm Central, with questions about the recall.
5. Call a physician or healthcare provider if you develop redness, swelling, drainage, fever, or other signs of infection after using the product.
6. Report any problem to the FDA’s MedWatch program. You can file online at www.fda.gov/medwatch/report.htm, or call 1-800-332-1088 to request a paper form.

Legal Options

A confirmed contamination recall can support a product-liability claim for someone who develops an infection linked to the cream. Even so, a recall does not automatically prove liability or create eligibility for compensation on MG217 Cream claims. No lawsuit over this recall has been filed, and no multidistrict litigation exists for it. A case depends on an individual legal review of your medical records and purchase.

Filing Deadlines

State law sets the filing deadline for a product-liability claim over MG217 Cream. The recall notice itself sets no deadline. That state-law deadline depends on where you live and on when the exposure, the infection, and the diagnosis happened. Missing a deadline can end a claim even when the underlying facts are strong, so the timing question is worth answering early rather than late. Anyone considering a claim over MG217 Cream should check with a lawyer promptly to learn the deadline that applies to their circumstances.

Frequently Asked Questions

What Are the Symptoms of a Staph Infection from MG217 Cream?

The symptoms of a Staphylococcus aureus infection from MG217 Cream include redness, swelling, warmth, or pus, according to MedlinePlus. The FDA’s risk statement warns that some infections can become more serious. These include bloodstream infection, infective endocarditis, bone or joint infection, or sepsis, particularly in people at higher risk.

Who Is at Highest Risk from the MG217 Cream Recall?

People at highest risk from the MG217 Cream recall include those with a weakened immune system. They also include those with compromised skin, such as open wounds, burns, or other skin disorders. A cut or wound gives Staphylococcus aureus bacteria an easier path into the body, per MedlinePlus.

Can I File a Lawsuit over the MG217 Cream Recall?

Yes, you can file a lawsuit over the MG217 Cream recall if you developed an infection. None has been filed yet, and no multidistrict litigation exists. The JPML’s pending-MDL list shows no MG217 or Pharmacal entry, so any claim would proceed as an individual case.

What Evidence Should I Keep If I Used the Recalled Cream?

If you used the recalled MG217 Cream, keep the tube with its visible lot number, along with any purchase receipt or order confirmation. Also keep photos of the product and any skin reaction, plus medical records for any care you sought.

What Is Staphylococcus Aureus?

Staphylococcus aureus, or staph, is a bacterium that about 30% of people carry on their skin or in the nose without illness. It can lead to infection after entering through a cut or wound, ranging from minor skin problems to serious bloodstream infections.

Can Staph Infections from Products Like MG217 Cream Spread to Other People?

Yes, staph infections from products like MG217 Cream can spread person to person. They can also spread on shared items like towels, clothing, or door handles. Anyone with a skin infection from the cream should avoid sharing personal items until it clears.

References

1. https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/pharmacal-issues-nationwide-recall-mg217-multi-symptom-treatment-cream-skin-protectant-eczema-cream
2. https://api.fda.gov/drug/enforcement.json?search=product_description:MG217+AND+recalling_firm:Pharmacal&limit=5
3. https://medlineplus.gov/staphylococcalinfections.html